The Federal Department of Home Affairs has adapted the Guidelines on Good Distribution Practice of Medicinal Products according to EU law. This move increases quality requirements for the distribution of medicinal products and strengthens patient protection.
Background and content of the GDP Guidelines
In 2011 the European Union (EU) enacted a new directive named “Falsified Medicines Directive” (Directive 2011/62/EU) with the aim of preventing counterfeit medicines from entering the legal supply chain. The Guidelines on Good Distribution Practice of Medicinal Products for Human Use (GDP Guidelines, 94/C 63/03 of 1 March 1994) were subsequently revised. The amended Guidelines (2013/C 343/01) came into force in the EU in September 2013. They aim to ensure the quality of all activities connected with the distribution of medicinal products (storage and transport conditions, etc.). However, some of the requirements specified in these new guidelines are stricter than before (as regards, for example, transport, outsourced activities, IT systems, etc.).
Revision of the Medicinal Products Licensing Ordinance
The GDP guidelines are part of the bilateral agreements between Switzerland and the EU (SR 946.526.81). By amending Appendix 2 of the Medicinal Products Licensing Ordinance (MPLO), Switzerland adopts the new guidelines and aligns its provisions with the stricter EU requirements. The equivalent requirements for the distribution of medicinal products aim to avoid trade obstacles for the Swiss exporting industry, while at the same strengthening patient protection. The revisions came into force on 1 July 2015, with a six-month implementation period until 1 January 2016.
Java script is required to display press releases. If you are unable or unwilling to activate Java script you may use the link below to access the Federal Administration News Portal, where you can read the announcements.
CC 812.212.1 Verordnung über die Bewilligungen im Arzneimittelbereich (in German, French and Italian)
Last modification 05.04.2019
Federal Office of Public Health FOPH
Division of Biomedicine
Therapeutic Products Law Section
Tel. +41 58 463 51 54